Connect with us
A study testing a low-dosage LSD treatment for adult attention-deficit/hyperactivity disorder (ADHD) didn’t pan out as planned. A new article in JAMA (Journal of American Medical...
New Mexico could become the third state in the country to legalize access to psilocybin if the Governor signs the proposed legislation. S.B. 219 also known...
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC: MDXXF) announced that it has contracted with a third-party logistics company specializing in pharmaceutical products to act as its...
Alto Neuroscience, Inc. (NYSE: ANRO) reported financial results for the full year ending December 31, 2024, highlighting recent progress across its pipeline of clinical-stage product candidates....
NRx Pharmaceuticals (NASDAQ: NRXP) filed a New Drug Application for its intravenous ketamine treatment for suicidal depression as it tries to expand its psychiatric clinic network,...
New Mexico Senate Bill 219, the Medical Psilocybin Act, moved a step closer to becoming a reality. The legislation would allow the use of psilocybin for qualified...
Atai Life Sciences (Nasdaq: ATAI) posted a $39 million net loss for the fourth quarter of 2024 but announced Monday that it boosted its financial position...
Toronto-based Neural Therapeutics (CSE: NURL) announced on Thursday a twofold milestone, with both the completion of a C$518,500 capital raise and the receipt of formal permission...
Incannex Healthcare Inc. (Nasdaq: IXHL) announced that it has raised $12.5 million to fund ongoing clinical trials. Incannex said the studies include completing the U.S. Phase...
Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced it is buying DiagnaMed Holdings Corp.’s (CSE: DMED) (OTCQB: DGNMF) intellectual property on molecular hydrogen as potential treatments...
